Biodesix Inc is a diagnostics & research business based in the US. Biodesix Inc shares (BDSX) are listed on the NASDAQ and all prices are listed in US Dollars. Biodesix Inc employs 218 staff and has a trailing 12-month revenue of around $31.3 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $1.35 |
|---|---|
| 52-week range | $1.23 - $8.75 |
| 50-day moving average | $2.02 |
| 200-day moving average | $2.50 |
| Wall St. target price | $5.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.82 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.35 from 2022-09-29
| 1 week (2022-09-23) | 5.47% |
|---|---|
| 1 month (2022-09-01) | -26.23% |
| 3 months (2022-07-01) | -17.68% |
| 6 months (2022-04-01) | -29.69% |
| 1 year (2021-10-01) | -84.43% |
|---|---|
| 2 years (2020-09-27) | N/A |
| 3 years (2019-09-27) | N/A |
| 5 years (2017-09-27) | N/A |
| Revenue TTM | $31.3 million |
|---|---|
| Gross profit TTM | $24 million |
| Return on assets TTM | -35.85% |
| Return on equity TTM | -336.12% |
| Profit margin | -179.84% |
| Book value | $0.19 |
| Market capitalisation | $51.2 million |
TTM: trailing 12 months
We're not expecting Biodesix Inc to pay a dividend over the next 12 months.
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc. , provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
